If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"","ctis_id":"","HasResults":"false","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"false","MaskingInfo":{"masked_assessor":"","masked_caregiver":"","masked_investigator":"","masked_subject":"","masking_description":"","no_masking":""},"PatientLevelData":"true","SharingIpd":"","acronym":"","allocation":"","arm_groups":[],"assignment":"","brief_summary":"","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"A Follow-On Study to Determine the Safety and Efficacy of Long-Term Lamivudine Treatment in Patients with Chronic Hepatitis B Infection (5 Year Treatment Plus 6 Months Off-treatment Follow-Up)","conditions":[{"DisplayValue":"Hepatitis B","DisplayValue_OneLinkTx":"","InternalValue":"CON_HEPATITIS_B","LookupValue":"Hepatitis B, Chronic","LookupValue_OneLinkTx":""}],"created_date":"03/04/2020 17:45:55","criteria":"Inclusion Criteria:\n -\nExclusion Criteria:\n -","detailed_description":"","display_gender":"","display_gender_internal":"","display_phase":"Phase 3","display_phase_internal":"PHASE_3","display_status":"Study Complete","display_status_internal":"RECSTATUS_STUDY_COMPLETED","endpoint":"","enrollment":"","exclusion":"","gender":"","gender_based":"","gender_description":"","healthy_volunteers":"","id":"da18142e-c300-596c-a46f-ff900dc2bd37","internal":{"content":null,"contentDigest":"1b4b6ef06f85ba9e79a6422f8b0b797b","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria:\n -\nExclusion Criteria:\n -","interventions":[],"interventional_subtype":"","is_fda_regulated":null,"is_high_value":false,"is_ind_study":null,"keywords":[],"last_follow_up_date":"01/31/2001 00:00:00","links":[],"locations":[],"masking":"","maximum_age_raw":"","maximum_age":null,"minimum_age":null,"minimum_age_raw":"","modified_date":"03/04/2020 17:45:55","number_of_arms":"","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Follow-On Study to Determine the Safety and Efficacy of Long-Term Lamivudine Treatment in Patients with Chronic Hepatitis B Infection (5 Year Treatment Plus 6 Months Off-treatment Follow-Up)","org_study_id":"NUCB3018","overall_contact":{"email":null,"last_name":null,"phone":null},"overall_status":"Completed","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":null,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 3","primary_compl_date":null,"primary_outcomes":[],"product_name":"lamivudine","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":[]},"start_date":"07/19/1995 00:00:00","study_type":"","therapeutic_area":"Infectious Diseases","citations":[{"citation":"Chang TT, Lai, CL, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B. J. of Gastroenterology and Hepatology 2004; 19, 1276-1282.","is_results_ref":"","pubmed_id":""},{"citation":"Lai CL, Chien RN, Leung NW et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998;339:61-8.","is_results_ref":"","pubmed_id":""},{"citation":"Leung NW, Lai CL, Chant TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after three years of therapy. Hepatology 2001;33:1527-32.","is_results_ref":"","pubmed_id":""},{"citation":"Liaw YF, Leung NW, Chang TT et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B.Gastroenterology 2000;119:172-80","is_results_ref":"","pubmed_id":""}],"is_section_801":null}},"pageContext":{"studyId":"NUCB3018"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}